Ionis Pharmaceuticals reaches 52-week high amid positive trial results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2024
0mins
Source: TipRanks
Ionis Pharmaceuticals Inc. saw a price increase of 5.51% as it reached a 52-week high, reflecting strong investor interest in the stock.
This surge is attributed to the successful Phase 3 trial results for Bepirovirsen in chronic hepatitis B treatment, demonstrating a significant functional cure rate. The trials involved over 1,800 patients across 29 countries, indicating a major advancement in treatment options and a strong market potential for the drug, which could address the needs of over 250 million people globally.
The positive results not only enhance Ionis's reputation in the biopharmaceutical sector but also position the company for substantial financial benefits, including up to $150 million in milestone payments from its collaboration with GSK, further solidifying its market presence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IONS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IONS
Wall Street analysts forecast IONS stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 74.310
Low
65.00
Averages
92.67
High
110.00
Current: 74.310
Low
65.00
Averages
92.67
High
110.00
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ionis Pharmaceuticals Appoints New Board Member
- New Board Member: Ionis Pharmaceuticals has appointed Ludwig Hantson to its Board of Directors, effective immediately, bringing over 30 years of leadership experience in the biopharmaceutical and medical device sectors, which will enhance the company's strategic direction.
- Rich Leadership Background: Hantson previously served as CEO and board member of Alexion from 2017 to 2021, a period marked by significant developments, particularly before its acquisition by AstraZeneca, showcasing his capability in navigating complex corporate environments.
- Strategic Development: CEO Brett P. Monia emphasized that Hantson's expertise in rare and specialty diseases will be invaluable as Ionis advances its commercial medicines and innovative pipeline, especially as the company enters a phase of accelerated growth and value creation.
- Stock Price Dynamics: Ionis's stock has fluctuated between $34.78 and $86.74 over the past year, currently trading at $74.17, down 0.42%, indicating a cautious market response to the company's new strategic direction.
See More
Ionis Pharmaceuticals Appoints Ludwig Hantson to Board of Directors
- New Board Member: Ionis Pharmaceuticals has appointed Dr. Ludwig Hantson to its Board of Directors effective immediately, bringing over 30 years of leadership experience in biopharma, which will be crucial as the company prepares for two independent commercial launches this year.
- Rich Leadership Background: Dr. Hantson previously served as CEO of Alexion, where he redefined the company's strategy and operating model before its acquisition by AstraZeneca, a background that will enhance Ionis's execution capabilities in a complex global market.
- Accelerated Growth Phase: According to Ionis CEO Brett P. Monia, Hantson's expertise will be invaluable as the company advances its commercial medicines and innovative pipeline, marking a new phase of accelerated growth and value creation for Ionis.
- Board Restructuring: Ionis also announced the appointment of Peter Reikes to the board and the retirement of long-serving directors Joseph Wender and Lynne Parshall, reflecting ongoing optimization and strategic adjustments in the company's governance structure.
See More
GSK's Antisense Drug Shows Promise in Hepatitis B Trials
- Clinical Trial Success: GSK's antisense drug bepirovirsen, developed with Ionis Pharma, achieved a 19% functional cure rate in two late-stage trials, significantly surpassing the current standard treatment's less than 1% cure rate, marking a new hope for chronic hepatitis B treatment.
- Significant Treatment Effects: In the B-Well 1 and B-Well 2 Phase 3 trials, six months of bepirovirsen therapy resulted in undetectable hepatitis B virus DNA and surface antigens for at least six months post-therapy, demonstrating clinically meaningful efficacy.
- Good Safety Profile: Conducted across 29 countries with chronic hepatitis patients, the studies indicated that bepirovirsen has an acceptable safety and tolerability profile consistent with previous trials, laying a solid foundation for its future market application.
- Long-term Impact Potential: GSK's science chief Tony Wood emphasized that bepirovirsen not only offers the potential for significantly improved functional cure rates but also may reduce the risk of long-term liver complications, including cancer, indicating a major advancement in chronic hepatitis B treatment.
See More
Bepirovirsen Shows Significant Efficacy in Chronic Hepatitis B Trials
- Functional Cure Breakthrough: In the pivotal B-Well 1 and B-Well 2 trials, bepirovirsen achieved a 19% functional cure rate overall and 26% in patients with lower viral activity, significantly outperforming the 0% rate of standard care, providing new hope for chronic hepatitis B patients.
- Significant Treatment Outcomes: Notably, 49% of bepirovirsen recipients achieved a hepatitis B surface antigen level of ≤100 IU/mL one year post-treatment, indicating enhanced immune control associated with a significant reduction in liver cancer risk, potentially improving patient outcomes.
- Global Impact: With over 240 million people affected by chronic hepatitis B, the successful development of bepirovirsen could transform treatment paradigms for this large patient population, reducing reliance on lifelong antiviral therapy and improving quality of life.
- Rapid Regulatory Progress: Bepirovirsen is currently under priority review by the FDA with Breakthrough and Fast Track Designations, with the first regulatory decisions anticipated in Q3 2026, highlighting its potential market value and prospects.
See More
Citi Initiates Bullish Coverage on SMid Cap Biotechs
- Analyst Rating Upgrade: Citi analyst Eric Joseph initiated Buy ratings on five biotech companies including Ionis (IONS), Alnylam (ALNY), and BioMarin (BMRN), reflecting a positive outlook for significant growth in the cardiovascular, metabolism, and endocrine sectors, which indicates strong confidence in the biotech industry.
- Ionis Price Target: The analyst set a $115 price target for Ionis, emphasizing that its pipeline based on antisense oligonucleotides provides a solid foundation for durable growth, showcasing confidence in its future performance.
- BioMarin Valuation Discount: BioMarin received a $75 price target, with analysts noting its EV/Rev ratio of 4x is significantly lower than peers' 8-9x, indicating a substantial valuation discount that may attract investor interest.
- Alnylam Investment Opportunity: Alnylam's price target is set at $380, with analysts arguing that despite its year-to-date underperformance, the impressive market launch of its heart disease therapy Amvuttra presents an attractive buying opportunity, signaling potential for future growth.
See More
Biogen's Alzheimer Therapy Trial Shows Promising Results
- Clinical Trial Results: Biogen's Phase 2 CELIA study indicates that diranersen, an experimental therapy for Alzheimer's disease, slowed clinical decline across all doses in early-stage patients, highlighting the drug's potential in treating Alzheimer's.
- Biomarker Impact: The study demonstrated significant reductions in tau pathology associated with Alzheimer's, providing the first evidence from a randomized Phase 2 trial of a tau-directed therapy showing robust biomarker impact and cognitive benefits.
- Safety and Tolerability: In the 416-patient trial, diranersen's safety and tolerability profile was consistent with data from a Phase 1b trial, reinforcing confidence in its safety characteristics for further development.
- Registration Development Outlook: Biogen expressed that the Phase 2 data gives them the confidence to advance diranersen into registrational development, indicating the drug's promising future in the Alzheimer's treatment landscape.
See More
Ionis Pharmaceuticals Appoints New Board Member
- New Board Member: Ionis Pharmaceuticals has appointed Ludwig Hantson to its Board of Directors, effective immediately, bringing over 30 years of leadership experience in the biopharmaceutical and medical device sectors, which will enhance the company's strategic direction.
- Rich Leadership Background: Hantson previously served as CEO and board member of Alexion from 2017 to 2021, a period marked by significant developments, particularly before its acquisition by AstraZeneca, showcasing his capability in navigating complex corporate environments.
- Strategic Development: CEO Brett P. Monia emphasized that Hantson's expertise in rare and specialty diseases will be invaluable as Ionis advances its commercial medicines and innovative pipeline, especially as the company enters a phase of accelerated growth and value creation.
- Stock Price Dynamics: Ionis's stock has fluctuated between $34.78 and $86.74 over the past year, currently trading at $74.17, down 0.42%, indicating a cautious market response to the company's new strategic direction.
See More
Ionis Pharmaceuticals Appoints Ludwig Hantson to Board of Directors
- New Board Member: Ionis Pharmaceuticals has appointed Dr. Ludwig Hantson to its Board of Directors effective immediately, bringing over 30 years of leadership experience in biopharma, which will be crucial as the company prepares for two independent commercial launches this year.
- Rich Leadership Background: Dr. Hantson previously served as CEO of Alexion, where he redefined the company's strategy and operating model before its acquisition by AstraZeneca, a background that will enhance Ionis's execution capabilities in a complex global market.
- Accelerated Growth Phase: According to Ionis CEO Brett P. Monia, Hantson's expertise will be invaluable as the company advances its commercial medicines and innovative pipeline, marking a new phase of accelerated growth and value creation for Ionis.
- Board Restructuring: Ionis also announced the appointment of Peter Reikes to the board and the retirement of long-serving directors Joseph Wender and Lynne Parshall, reflecting ongoing optimization and strategic adjustments in the company's governance structure.
See More
GSK's Antisense Drug Shows Promise in Hepatitis B Trials
- Clinical Trial Success: GSK's antisense drug bepirovirsen, developed with Ionis Pharma, achieved a 19% functional cure rate in two late-stage trials, significantly surpassing the current standard treatment's less than 1% cure rate, marking a new hope for chronic hepatitis B treatment.
- Significant Treatment Effects: In the B-Well 1 and B-Well 2 Phase 3 trials, six months of bepirovirsen therapy resulted in undetectable hepatitis B virus DNA and surface antigens for at least six months post-therapy, demonstrating clinically meaningful efficacy.
- Good Safety Profile: Conducted across 29 countries with chronic hepatitis patients, the studies indicated that bepirovirsen has an acceptable safety and tolerability profile consistent with previous trials, laying a solid foundation for its future market application.
- Long-term Impact Potential: GSK's science chief Tony Wood emphasized that bepirovirsen not only offers the potential for significantly improved functional cure rates but also may reduce the risk of long-term liver complications, including cancer, indicating a major advancement in chronic hepatitis B treatment.
See More
Bepirovirsen Shows Significant Efficacy in Chronic Hepatitis B Trials
- Functional Cure Breakthrough: In the pivotal B-Well 1 and B-Well 2 trials, bepirovirsen achieved a 19% functional cure rate overall and 26% in patients with lower viral activity, significantly outperforming the 0% rate of standard care, providing new hope for chronic hepatitis B patients.
- Significant Treatment Outcomes: Notably, 49% of bepirovirsen recipients achieved a hepatitis B surface antigen level of ≤100 IU/mL one year post-treatment, indicating enhanced immune control associated with a significant reduction in liver cancer risk, potentially improving patient outcomes.
- Global Impact: With over 240 million people affected by chronic hepatitis B, the successful development of bepirovirsen could transform treatment paradigms for this large patient population, reducing reliance on lifelong antiviral therapy and improving quality of life.
- Rapid Regulatory Progress: Bepirovirsen is currently under priority review by the FDA with Breakthrough and Fast Track Designations, with the first regulatory decisions anticipated in Q3 2026, highlighting its potential market value and prospects.
See More
Citi Initiates Bullish Coverage on SMid Cap Biotechs
- Analyst Rating Upgrade: Citi analyst Eric Joseph initiated Buy ratings on five biotech companies including Ionis (IONS), Alnylam (ALNY), and BioMarin (BMRN), reflecting a positive outlook for significant growth in the cardiovascular, metabolism, and endocrine sectors, which indicates strong confidence in the biotech industry.
- Ionis Price Target: The analyst set a $115 price target for Ionis, emphasizing that its pipeline based on antisense oligonucleotides provides a solid foundation for durable growth, showcasing confidence in its future performance.
- BioMarin Valuation Discount: BioMarin received a $75 price target, with analysts noting its EV/Rev ratio of 4x is significantly lower than peers' 8-9x, indicating a substantial valuation discount that may attract investor interest.
- Alnylam Investment Opportunity: Alnylam's price target is set at $380, with analysts arguing that despite its year-to-date underperformance, the impressive market launch of its heart disease therapy Amvuttra presents an attractive buying opportunity, signaling potential for future growth.
See More
Biogen's Alzheimer Therapy Trial Shows Promising Results
- Clinical Trial Results: Biogen's Phase 2 CELIA study indicates that diranersen, an experimental therapy for Alzheimer's disease, slowed clinical decline across all doses in early-stage patients, highlighting the drug's potential in treating Alzheimer's.
- Biomarker Impact: The study demonstrated significant reductions in tau pathology associated with Alzheimer's, providing the first evidence from a randomized Phase 2 trial of a tau-directed therapy showing robust biomarker impact and cognitive benefits.
- Safety and Tolerability: In the 416-patient trial, diranersen's safety and tolerability profile was consistent with data from a Phase 1b trial, reinforcing confidence in its safety characteristics for further development.
- Registration Development Outlook: Biogen expressed that the Phase 2 data gives them the confidence to advance diranersen into registrational development, indicating the drug's promising future in the Alzheimer's treatment landscape.
See More
